| Molecular prediction of durable remission after first-line fludarabine-cyclophosphamide-rituximab in chronic lymphocytic leukemia D Rossi, L Terzi-di-Bergamo, L De Paoli, M Cerri, G Ghilardi, A Chiarenza, ... Blood, The Journal of the American Society of Hematology 126 (16), 1921-1924, 2015 | 263 | 2015 |
| Gut microbiome correlates of response and toxicity following anti-CD19 CAR T cell therapy M Smith, A Dai, G Ghilardi, KV Amelsberg, SM Devlin, R Pajarillo, ... Nature medicine 28 (4), 713-723, 2022 | 152 | 2022 |
| Genetic and phenotypic attributes of splenic marginal zone lymphoma F Bonfiglio, A Bruscaggin, F Guidetti, L Terzi di Bergamo, M Faderl, ... Blood, The Journal of the American Society of Hematology 139 (5), 732-747, 2022 | 56 | 2022 |
| Bendamustine is safe and effective for lymphodepletion before tisagenlecleucel in patients with refractory or relapsed large B-cell lymphomas G Ghilardi, EA Chong, J Svoboda, P Wohlfarth, SD Nasta, S Williamson, ... Annals of Oncology 33 (9), 916-928, 2022 | 40 | 2022 |
| Daratumumab for relapsed or refractory AL amyloidosis with high plasma cell burden R Schwotzer, MG Manz, S Pederiva, C Waibel, C Caspar, E Lerch, ... Hematological oncology 37 (5), 595-600, 2019 | 32 | 2019 |
| Modulation of BCL-2 in both T cells and tumor cells to enhance chimeric antigen receptor T-cell immunotherapy against cancer YG Lee, P Guruprasad, G Ghilardi, R Pajarillo, CT Sauter, R Patel, ... Cancer discovery 12 (10), 2372-2391, 2022 | 25 | 2022 |
| CAR‐T TREK through the lymphoma universe, to boldly go where no other therapy has gone before G Ghilardi, P Braendstrup, EA Chong, SJ Schuster, J Svoboda, M Ruella British Journal of Haematology 193 (3), 449-465, 2021 | 23 | 2021 |
| Venetoclax plus daratumumab induce hematological CR and organ response in an AL amyloidosis patient with t (11; 14) G Ghilardi, G Stussi, L Mazzucchelli, C Röcken, D Rossi, B Gerber Amyloid 26 (3), 173-174, 2019 | 21 | 2019 |
| Melphalan dose in myeloma patients≥ 65 years of age undergoing high-dose therapy and autologous stem cell transplantation: a multicentric observational registry study G Ghilardi, T Pabst, B Jeker, R Müller, A Cairoli, AMS Müller, M Bargetzi, ... Bone marrow transplantation 54 (7), 1029-1037, 2019 | 19 | 2019 |
| Modulation of the gut microbiota engages antigen cross-presentation to enhance antitumor effects of CAR T cell immunotherapy M Uribe-Herranz, S Beghi, M Ruella, K Parvathaneni, S Salaris, ... Molecular Therapy 31 (3), 686-700, 2023 | 14 | 2023 |
| T cell lymphoma and secondary primary malignancy risk after commercial CAR T cell therapy G Ghilardi, JA Fraietta, JN Gerson, VM Van Deerlin, JJD Morrissette, ... Nature Medicine, 1-6, 2024 | 11 | 2024 |
| Clinical characteristics and outcome of patients over 60 years with Hodgkin lymphoma treated in Switzerland AA Moccia, S Aeppli, S Güsewell, M Bargetzi, C Caspar, D Brülisauer, ... Hematological oncology 39 (2), 196-204, 2021 | 10 | 2021 |
| Integration of baseline metabolic parameters and mutational profiles predicts long-term response to first-line therapy in DLBCL patients: a post hoc analysis of the SAKK38/07 study S Genta, G Ghilardi, L Cascione, D Juskevicius, A Tzankov, S Schär, ... Cancers 14 (4), 1018, 2022 | 7 | 2022 |
| Bendamustine is a safe and effective regimen for lymphodepletion before tisagenlecleucel in patients with large B-cell lymphomas G Ghilardi, EA Chong, J Svoboda, P Wohlfarth, SD Nasta, S Williamson, ... Blood 138, 1438, 2021 | 5 | 2021 |
| The intestinal microbiota correlates with response and toxicity after CAR T cell therapy in patients with B-cell malignancies M Smith, A Dai, G Ghilardi, K Amelsberg, SM Devlin, R Pajarillo, ... Blood 138, 253, 2021 | 4 | 2021 |
| Clinical development of Senza5TM CART5: a novel dual population CD5 CRISPR-Cas9 knocked out anti-CD5 chimeric antigen receptor T cell product for relapsed and refractory CD5+ … RP Patel, G Ghilardi, P Porazzi, S Yang, D Qian, R Pajarillo, M Wang, ... Blood 140 (Supplement 1), 1604-1605, 2022 | 3 | 2022 |
| CAR T-cell immunotherapy in minority patients with lymphoma G Ghilardi, S Williamson, R Pajarillo, L Paruzzo, L Chen, C Grady, ... NEJM Evidence 3 (4), EVIDoa2300213, 2024 | 2 | 2024 |
| Bendamustine lymphodepletion before axicabtagene ciloleucel is safe and associates with reduced inflammatory cytokines G Ghilardi, L Paruzzo, J Svoboda, EA Chong, AA Shestov, L Chen, ... Blood Advances 8 (3), 653-666, 2024 | 2 | 2024 |
| Author Correction: Gut microbiome correlates of response and toxicity following anti-CD19 CAR T cell therapy M Smith, A Dai, G Ghilardi, KV Amelsberg, SM Devlin, R Pajarillo, ... Nature medicine 29 (11), 2954-2954, 2023 | 2 | 2023 |
| Anti-PD-L1 monoclonal antibody for the management of chronic disseminated intravascular coagulation secondary to a urothelial carcinoma: a case report S Maiorano, W Gulden-Sala, B Gerber, G Ghilardi Journal of Medical Case Reports 16 (1), 113, 2022 | 2 | 2022 |
